Takeda’s dengue vaccine candidate delivers continued protection
Vital dengue vaccine offers over four years’ protection following successful clinical trial
Read More
Tag: Dengue
Takeda’s dengue vaccine bags positive long-term efficacy results
Vaccine candidate demonstrated 83.6% efficacy against hospitalisation three years after vaccination
Read More
Dengvaxia approved for dengue in EU
The European Commission has granted marketing authorisation for Sanofi’s dengue vaccine Dengvaxia.
Read More
- Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
- Atrogi begins dosing first subjects in human trial of ATR-258
- R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment
- Taiwan Bio partners with Terumo to advance automated Treg manufacturing
- Elevara begins phase 2b trial of ELV001 in rheumatoid arthritis
